US Health Reform Rows "Preview Presidential Race"
Health Reform Rows "Preview Presidential Race"
The fight over the medical savings account provision in the US health insurance reform bill is being seen as a preview of the upcoming presidential campaign, and the issues involved are turning into a major presidential campaign confrontation.
Some Republicans say that if President Clinton makes good his promise to veto any bill with MSAs (Marketletter April 15), he will take the blame for losing the basic portable-insurance bill; the President has since told a news conference that the bill should be passed "unadorned, simple, strong and good." The Democrats feel Senator Bob Dole will take the blame for a veto, and will eventually realize that the MSA provision is a political liability since it is supported by officers of Golden Rule Insurance, who have contributed heavily to GOP causes. Critics of the MSA plan note that individuals cannot do much to reduce their health care spending, since most decisions are really made by doctors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze